The pharmacotherapy of catatonia

Primary Psychiatry

Volumn 17, Issue 4, 2010, Pages 41-47

  Carroll, Brendan T ^a   Lee, Joseph W Y ^b   Appiani, Francisco ^c   Thomas, Christopher ^d  

^a OHIO UNIVERSITY   (United States)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; AMANTADINE; AMISULPRIDE; ANTICONVULSIVE AGENT; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; BROMOCRIPTINE; CARBAMAZEPINE; CARBIDOPA PLUS LEVODOPA; CLONAZEPAM; CLOZAPINE; GLUTAMATE RECEPTOR ANTAGONIST; HALOPERIDOL; LITHIUM; LORAZEPAM; MEMANTINE; NEUROLEPTIC AGENT; PROMETHAZINE; QUETIAPINE; RISPERIDONE; SELEGILINE; SEROTONIN; SERTRALINE; THIORIDAZINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE; ZIPRASIDONE; ZOLPIDEM;

ARTICLE; AUTISM; CATATONIA; CHOLINERGIC SYSTEM; DELUSION; DEVELOPMENTAL DISORDER; DISEASE COURSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DYSTHYMIA; ELECTROCONVULSIVE THERAPY; HALLUCINATION; HUMAN; MANIA; MENTAL DISEASE; MONOTHERAPY; MOOD DISORDER; NEUROCHEMISTRY; NEUROLOGIC DISEASE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; PSYCHOSIS;

EID: 77951728145     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Abrams R, Taylor MA. Catatonia. A prospective clinical study. Arch Gen Psychiatry. 1976;33(5):579-581.
2. Ahmed I, Fujii D, eds. The Spectrum of Psychotic Disorders, Neurobiology, Etiology & Pathogenesis. New York, NY: Cambridge University Press; 2007.
3. Barnes MP, Saunders M, Walls TJ, Saunders I, Kirk CA. The syndrome of Karl Ludwig Kahlbaum. J Neurol Neurosurg Psychiatry. 1986;49(9):991-996.
4. Northoff G. What catatonia can tell us about "top-down modulation": a neuropsychiatric hypothesis. Behav Brain Sci. 2002;25(5):555-577.
5. Yeh AW, Lee JW, Cheng TC, Wen JK, Chen WH. Clozapine withdrawal catatonia associated with cholinergic and serotonergic rebound hyperactivity: a case report. Clin Neuropharmacol. 2004;27(5):216-218.
6. Kahlbaum KL; Levij Y, Pridon T, Trans. Catatonia. Baltimore, MD: Johns Hopkins University Press; 1973.
7. Dhossche DM, Wilson C, Wachtel LE. Catatonia in childhood and adolescence: implications for the DSM-5. Primary Psychiatry. 2010;17(4):35-39.
8. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washinton, DC: American Psychiatric Association; 1994.
9. Ungvari GS, Chiu HF, Chow LY, Lau BS, Tang WK. Lorazepam for chronic catatonia: a randomized, double-blind, placebo-controlled cross-over study. Psychopharmacology (Berl). 1999;142(4):393-398.
10. van der Heijden F, Tuinier S, Arts N, Hoogendoorn M, Kahn R, Verhoeven W. Catatonia: disappeared or under-diagnosed? Psychopathology. 2005;38(1):3-8.
11. Stompe T, Ortwein-Swoboda G, Ritter K, Schanda H, Friedmann A. Are we witnessing the disappearance of catatonic schizophrenia? Compr Psychiatry. 2002;43(3):167-174.
12. Rosebush PI, Mazurek MF. Catatonia: re-awakening to a forgotten disorder. Mov Disord. 1999;14(3):395-397.
13. Lund CE, Mortimer AM, Rogers D, McKenna PJ. Motor, volitional and behavioural disorders in schizophrenia. I. Assessment using the Modified Rogers Scale. Br J Psychiatry. 1991;158:323-327,333-336.
14. Bush G, Fink M, Petrides G, Dowling F, Francis A. Catatonia. I. Rating scale and standardized examination. Acta Psychiatr Scand. 1996;93(2):129-136.
15. Northoff G, Koch A, Wenke J, et al. Catatonia as a psychomotor syndrome: a rating scale and extrpyramidal motor symptoms. Mov Disord. 1999;14(3):404-416.
16. Bräunig P, Krüger S, Shugar G, Höffler J, Börner I. The catatonia rating scale I--development, reliability and use. Compr Psychiatry. 2000;41(2):147-158.
17. Carroll BT, Kirkhart R, Ahuja N, et al. Katatonia: a new conceptual understanding of catatonia and a new rating scale. Psychiatry (Edgemont). 2008;5(12):42-50.
18. Brenner I, Rheuban WJ. The catatonic dilemma. Am J Acta Psychiatry. 1978;135(10):1242-1243.
19. Lee JW. Neuroleptic-induced catatonia: clinical presentation, response to benzodiazepines, and relationship to neuroleptic malignant syndrome. J Clin Psychopharmacol. 2010;30(1):3-10.
20. Carroll BT, Carroll TD, Lee JW, et al. Why are some medications effective against catatonia? Int J Neuropsychopharmacology. 2006;9(suppl 1):S253.
21. Lee JW, Carroll BT. Amantadine in the treatment of chronic catatonic schizophrenia. Int J Neuropsychopharmacology. 2006;9(suppl 1):S270.
22. Rosebush PI, Hildebrand AM, Furlong BG, Mazurek MF. Catatonic syndrome in a general psychiatric population: frequency, clinical presentation, and response to lorazepam. J Clin Psychiatry. 1990;51(9):357-362.
23. Lohr JB, Wisenewski AA. Movement Disorders: A Neuropsychiatric Approach. New York, NY: Guilford Press; 1987.